Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
US9938346B2 · kind B2 · utility
0Cited by
6References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 26, 2016 |
| Grant date | Apr 10, 2018 |
| Priority date | — |
| Expiry date | Sep 30, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.